Goldfinch Bio Bolsters Leadership Team by Appointing Dr. Peter Mundel as Chief Scientific Officer and Electing Dr. Frank Maddux to Board of Directors

Cambridge, Mass., March 13, 2018 – Goldfinch Bio, a company focused on precision therapies to treat patients with kidney disease, today announced the strengthening of its leadership team with the election of Franklin “Frank” W. Maddux, M.D. F.A.C.P., to its board of directors and naming Dr. Peter Mundel, M.D., chief scientific officer. Dr. Mundel, an expert in kidney podocyte biology, played a key role in the creation and launch of Goldfinch Bio and has been instrumental in its progress to date.  Dr. Maddux, an expert nephrologist, currently serves as chief medical officer (CMO) and executive vice president of clinical and scientific affairs at Fresenius Medical Care North America.

“Peter Mundel has been a critical team member in the early days of Goldfinch Bio laying the scientific groundwork for our evolving pipeline,” stated Tony Johnson, M.D., chief executive officer of Goldfinch Bio. “Together with our outstanding scientific and development leadership team Peter has helped integrate breakthroughs in genetics and biology to bring precision medicine closer to patients with kidney diseases.”

About Peter Mundel, M.D.
Dr. Mundel joined Goldfinch Bio after serving as a consultant to Third Rock Ventures, where he played an important role in the creation and launch of Goldfinch Bio. He brings to the company more than 25 years of experience as a leader in academic research, most recently at Massachusetts General Hospital and Harvard Medical School. A major focus of Dr. Mundel’s work has been the development of precision therapeutics for patients with kidney diseases through a mechanistic understanding of the cell biology and pathophysiology of the kidney, with a focus on podocytes. A pioneer of molecularly targeted treatment for proteinuric kidney disease, Dr. Mundel has published more than 150 peer-reviewed manuscripts, including in high impact journals such as the New England Journal of Medicine, Nature Medicine, and Nature Cell Biology, and has given numerous invited lectures nationally and internationally. He was inducted into the American Society for Clinical Investigation in 2003, and has received numerous awards including a Top10 award from the Clinical Research Forum and the Young Investigator Award from the American Society of Nephrology. Dr. Mundel holds an M.D. from the University of Heidelberg, Germany.

“I am pleased to add Dr. Frank Maddux to our Board given his expertise across the medical and business aspects of kidney disease,” noted Dr. Johnson. “As Goldfinch develops precision therapies for kidney disease patients, we will benefit greatly from Dr. Maddux’s decades of experience, patient care, and commitment alongside renal stakeholders to improve treatment of kidney disease.”

About Frank Maddux, M.D.
Dr. Maddux brings more than three decades of experience as a physician, nephrologist, and healthcare executive. He currently serves as CMO and executive vice president for clinical and scientific affairs for Fresenius Medical Care North America, where he oversees the delivery of quality, value-based care for the largest integrated renal care network in North America. Dr. Maddux joined Fresenius Medical Care in 2009 after the company acquired Health IT Services Group, a leading electronic health record (EHR) software company founded by Maddux. Prior to joining Fresenius Medical Care North America, he served as CMO and senior vice president for Specialty Care Services Group and formerly served as president of Virginia’s Danville Urologic Clinic, where he was a practicing nephrologist for nearly two decades. In 2017, Dr. Maddux was nominated as one of Modern Healthcare Magazine’s 50 Most Influential Physician Executives in the U.S. He holds a BS in mathematics from Vanderbilt University and an MD degree from the School of Medicine at the University of North Carolina at Chapel Hill.

“Goldfinch Bio is evolving a disciplined scientific and genetic registry-based approach to realize the goal of helping to deliver precise personalized care for patients with kidney disease,” stated Dr. Maddux.

About Goldfinch Bio
Goldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for patients with kidney diseases. Just as the goldfinch has long been a symbol of healing and renewal and was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for patients with kidney diseases. Goldfinch was launched in 2016 by Third Rock Ventures, and is headquartered in Cambridge, Mass. For more information, please visit

Goldfinch Bio Contact
Jennifer Williams
Cook Williams Communications, Inc.

Press ReleasesAdam Tebbe